Marea therapeutics presents preclinical data on novel growth hormone receptor antagonist antibody, mar002, for the treatment of acromegaly at endo 2025

South san francisco, calif.--(business wire)--marea therapeutics, inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on mar002, a novel growth hormone receptor (ghr) antagonist antibody for the treatment of acromegaly, at the 2025 annual meeting of the endocrine society (endo). the oral presentation, titled “developmen.
MAR Ratings Summary
MAR Quant Ranking